The following abstracts represent the oral presentations given at IWWM-12 (Prague-2024), Session 10: Chemoimmunotherapy in WM I
Session Chairs: Shirley D'Sa, M. J. Kersten
Dexamethasone, rituximab, and cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM Buske (Germany)
Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM Leblond (France)
Multicenter Observational Study of Benda-Rituximab vs. RCD Autore (Italy)
Long-term Outcomes of 678 patients with symptomatic WM Askari (Spain)